About Holly Archer

This author has not yet filled in any details.
So far Holly Archer has created 19 blog entries.

Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1)

By |2021-05-17T18:52:31+01:00August 5th, 2020|News, Nityr|

Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in the Kingdom of Saudi Arabia

By |2021-05-17T18:52:31+01:00May 13th, 2020|News, Nityr|

Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology

By |2021-05-17T18:52:31+01:00May 5th, 2020|News, Nityr|

Cycle Pharmaceuticals Launches New Informative Online Meeting Series for Patients With Tyrosinemia Type 1 in the US

By |2021-05-17T18:52:31+01:00April 19th, 2020|News, Resource|

Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics

By |2021-05-17T18:52:31+01:00December 18th, 2019|News, Nityr|

Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases using Zydis ODT Technology

By |2022-01-28T15:52:20+00:00October 31st, 2019|News, Nityr|

NITYR (nitisinone) Tablets for tyrosinaemia type 1 will be available with fully subsidised access on the Life Saving Drugs Program across Australia

By |2021-05-17T18:52:31+01:00April 28th, 2019|News, Nityr|

Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDA

By |2021-05-17T18:52:31+01:00November 19th, 2018|News, Nityr|

Cycle Pharmaceuticals Receives Approval for Updated Infant Administration for NITYR (nitisinone) Tablets for HT-1 in U.S.

By |2021-05-17T18:52:31+01:00November 12th, 2018|News, Nityr|
Go to Top